- Home
- MTEX vs IGC Comparison
MTEX vs IGC Comparison
Compare MTEX & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- IGC
- Stock Information
- Founded
- MTEX 1993
- IGC 2005
- Country
- MTEX United States
- IGC United States
- Employees
- MTEX N/A
- IGC N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- IGC Health Care
- Exchange
- MTEX Nasdaq
- IGC Nasdaq
- Market Cap
- MTEX 21.2M
- IGC 19.1M
- IPO Year
- MTEX 1999
- IGC N/A
- Fundamental
- Price
- MTEX $7.93
- IGC $0.28
- Analyst Decision
- MTEX
- IGC Strong Buy
- Analyst Count
- MTEX 0
- IGC 2
- Target Price
- MTEX N/A
- IGC $3.88
- AVG Volume (30 Days)
- MTEX 4.6K
- IGC 355.0K
- Earning Date
- MTEX 05-13-2025
- IGC 02-18-2025
- Dividend Yield
- MTEX N/A
- IGC N/A
- EPS Growth
- MTEX N/A
- IGC N/A
- EPS
- MTEX 1.32
- IGC N/A
- Revenue
- MTEX $117,866,000.00
- IGC $1,236,000.00
- Revenue This Year
- MTEX N/A
- IGC N/A
- Revenue Next Year
- MTEX N/A
- IGC $18.34
- P/E Ratio
- MTEX $6.38
- IGC N/A
- Revenue Growth
- MTEX N/A
- IGC 1.65
- 52 Week Low
- MTEX $6.75
- IGC $0.26
- 52 Week High
- MTEX $16.49
- IGC $0.91
- Technical
- Relative Strength Index (RSI)
- MTEX 25.06
- IGC 40.33
- Support Level
- MTEX $8.21
- IGC $0.29
- Resistance Level
- MTEX $9.20
- IGC $0.32
- Average True Range (ATR)
- MTEX 0.51
- IGC 0.02
- MACD
- MTEX -0.13
- IGC -0.00
- Stochastic Oscillator
- MTEX 7.42
- IGC 2.83
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.